No draft has been generated for John Muolo under any (sender, voice, purpose, target-role) combination yet.
Location: UK/US · Frame: chair/advisor (reframed from Frame B per multi-agent convergence) · Judge tier: BN · Judge Focus-44 rank: 15
Ergéa UK EVP & Director Strategic Relationships (post-Medipass sale)
_Company: Ergéa UK / Ergéa Group._
Reed Smith Partner (US Health Care) 2002+ → co-founded Medipass Healthcare → CEO Medipass 2008-2022 → 2022 Ergéa merger realised the exit.
Medipass co-founder + 14yr CEO 2008-2022 (Ex-Reed Smith Partner Health Care 2002+); 2022 Ergéa merger realised liquidity; currently EVP not top-of-house (Rolfe Group CEO + Graves UK CEO above).
JD Pittsburgh 1984-87 + BS Susquehanna + MS George Washington; Reed Smith Partner Health Care; Nations Healthcare founding CEO; Medipass co-founded with DAVID ROLFE (Lin 44-walk P4 cross-link — same Medipass).
TALENT brr v5 primary-source (msg-th3v46): RAD 2012 confirms Muolo Director alongside Rolfe as CEO; LinkedIn co-founder claim NOT primary-source-explicit. Rolfe (Group CEO) + Graves (UK CEO) sit above him at Ergéa currently. Founder claim medium-confidence; not-top-of-house observation stands. Tier 1.5 chair/advisor reframe holds.
OPEN (post-liquidity)
Outreach window: Later — chair/advisor NOT founder-back
Rolfe (Ergéa Group CEO, 14yr Medipass colleague) is strongest peer link
chair/advisor (reframed from Frame B per multi-agent convergence) · Founder-back (historic) · L4 bracket CONTRARIAN · L1=3 L2=3 L4=3 L5=4 L6=3
Path to seat: sold_and_stayed_founder_now_advisory
Data gap: Frame confirmed as chair/advisor not founder-back per Talent v5 + Lin v9
Data gap: L6 evidence-only rescore: Whitepaper thought-leadership + webinar-speaker + advisory role = advisory-drift not founder-back per multi-agent read